MERCK MK-476 LEUKOTRIENE ANTAGONIST NDA FILING FOR ASTHMA PROJECTED FOR 1996; PROSCAR FOR BALDNESS SET FOR PHASE III IN LATE 1994, ANALYSTS TOLD
Executive Summary
Merck is projecting a 1996 NDA filing for MK-476, its latest developmental candidate in the leukotriene antagonist asthma treatment field.